Stockscreener 앱 받기
41.26
0.00%
0.00
시간 외 거래:
40.80
-0.46
-1.11%
Exelixis Inc 주식(EXEL)의 최신 뉴스
How Exelixis Inc. (EXEL) Affects Rotational Strategy Timing - Stock Traders Daily
Pharma Stocks Analysis 2026: Pfizer & Novo Nordisk Rebound, Exelixis GrowthNews and Statistics - IndexBox
Here's why Exelixis (EXEL) is a strong value stock - MSN
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
The Best Healthcare Stocks to Buy With $50 Right Now - The Motley Fool
Portfolio Update: What is the earnings history of Exelixis Inc2026 Highlights & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Exelixis (EXEL) Valuation After Earnings Beat FDA Progress And Cabometyx Label Expansion - Yahoo Finance
Exelixis Highlights Zanzalintinib RCC Trials, Sequencing Debate, and December CRC PDUFA at Leerink - Yahoo Finance
Exelixis Highlights CABOMETYX Growth, Zanzalintinib PDUFA and Pipeline Strategy at Barclays Conference - Yahoo Finance
Exelixis Highlights $2.4B 2026 Outlook, Cabometyx Momentum and Zanzalintinib Catalysts at Conference - Yahoo Finance
Exelixis Inc Stock (ISIN: US30161Q1040) Gains Momentum on Earnings Beat and Zanzalintinib FDA Milest - AD HOC NEWS
How Exelixis’ Earnings Beat and FDA Zanzalintinib Milestone Will Impact Exelixis (EXEL) Investors - simplywall.st
EXEL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
EXEL SEC FilingsExelixis Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Exelixis (EXEL) Valuation After Analysts Lift 2026 Earnings Forecasts - simplywall.st
Here's why Exelixis (EXEL) is a strong growth stock - MSN
Exelixis (EXEL) Down 2.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Here’s What Makes Exelixis (EXEL) a Top Growth Stock - Bitget
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Exelixis at Barclays Healthcare: Strategic Growth and Pipeline Insights By Investing.com - Investing.com Canada
EXEL: Zanzalintinib and CABOMETYX anchor growth in GI/GU oncology, with robust pipeline momentum - TradingView
EXEL: Zanza and new indications drive growth, targeting $2.4B revenue and leadership in key oncology markets - TradingView
First Trust Advisors LP Has $59.35 Million Holdings in Exelixis, Inc. $EXEL - MarketBeat
Barclays PLC Boosts Stock Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis at Leerink Global Healthcare Conference: Strategic Insights in RCC and CRC - Investing.com Canada
Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion - Investing.com Nigeria
Dimensional Fund Advisors LP Grows Holdings in Exelixis, Inc. $EXEL - MarketBeat
Victory Capital Management Inc. Acquires 187,034 Shares of Exelixis, Inc. $EXEL - MarketBeat
What is Zacks Research's Estimate for Exelixis Q3 Earnings? - MarketBeat
Crossmark Global Holdings Inc. Boosts Stock Position in Exelixis, Inc. $EXEL - MarketBeat
Exelixis, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
(EXEL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Teton Advisors LLC Makes New Investment in Exelixis, Inc. $EXEL - MarketBeat
Exelixis (NASDAQ:EXEL) Cut to Hold at Zacks Research - MarketBeat
Gainers Report: Will Exelixis Inc benefit from rising consumer demandWeekly Trend Summary & Smart Investment Allocation Tips - baoquankhu1.vn
Exelixis, Inc. (NASDAQ:EXEL) Given Average Recommendation of "Hold" by Analysts - MarketBeat
American Century Companies Inc. Raises Position in Exelixis, Inc. $EXEL - MarketBeat
Elo Mutual Pension Insurance Co Buys 30,279 Shares of Exelixis, Inc. $EXEL - MarketBeat
A Look At Exelixis (EXEL) Valuation As Analyst Optimism Builds Around Its Oncology Pipeline - simplywall.st
EXEL: Zanzalintinib advances toward launch as pivotal trials and franchise expansion drive future growth - TradingView
Forecasting The Future: 11 Analyst Projections For Exelixis - Sahm
Is Improving Analyst Sentiment Reframing Exelixis (EXEL) Oncology Pipeline As A Core Valuation Anchor? - simplywall.st
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Exelixis (EXEL) and Sarepta Therapeutics (SRPT) - The Globe and Mail
Exelixis (NASDAQ: EXEL) GC awarded 23,119 RSU-based common shares - Stock Titan
Exelixis (NASDAQ: EXEL) CEO granted RSUs, gifts 100K shares - Stock Titan
Exelixis stock falls after rival Merck trial shows better results By Investing.com - Investing.com India
Exelixis stock falls after rival Merck trial shows better results - Investing.com Australia
RBC Capital Lowers Exelixis (EXEL) Price Target to $43 | EXEL St - GuruFocus
Royal Bank Of Canada Issues Pessimistic Forecast for Exelixis (NASDAQ:EXEL) Stock Price - MarketBeat
Why Exelixis (EXEL) Stands Out as a Leading Value Investment for Long-Term Growth - Bitget
Exelixis (NASDAQ:EXEL) Shares Down 9.4% After Analyst Downgrade - MarketBeat
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating - marketscreener.com
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Growth With A 7.05% Potential Upside - DirectorsTalk Interviews
Exelixis (NASDAQ:EXEL) Downgraded by Wall Street Zen to Buy - MarketBeat
Exelixis Aims to Expand Beyond Cabozantinib Franchise - Intellectia AI
Exelixis Aims to Become a Top Oncology Player with Expanding Pipeline - Intellectia AI
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade - Nasdaq
Citigroup Inc. Sells 365,552 Shares of Exelixis, Inc. $EXEL - MarketBeat
EXEL PE Ratio & Valuation, Is EXEL Overvalued - Intellectia AI
EXEL Should I Buy - Intellectia AI
1.20%
0.06%
자본화:
|
볼륨(24시간):